SalvaRx Group PLC (SalvaRx) is a drug development company focused on acquiring and operating drug development programmes in immuno-oncology. It owns 60.49% of iOx Therapeutics Limited, a company that is developing a pipeline of anti-cancer treatments based on iNKT cells under license from the Ludwig Institute for Cancer Research. SalvaRx’s strategy focuses on the acquisition of immune-oncology therapeutics that are complementary to anti-PD1 or anti-PDL1 therapies. The Company uses a group of industry and academic experts to assess information on acquisition and investment targets. SalvaRx joined AIM on 22 March 2016 via a reverse takeover of 3Legs Resources PLC.
|Name||Number of Shares||Percentage|
|Dr. Gregory Bailey||13,320,291||36.53%|
|Hon & Co Holdings Limited||2,122,676||5.79%|